Article Contents ::
- 1 Details About Generic Salt :: Cycloser
- 2 Main Medicine Class:: Anti-infective,Antitubercular
- 3 (sigh-kloe-SER-een) Seromycin Pulvules Class: Anti-infective/Antitubercular
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Cycloser
Main Medicine Class:: Anti-infective,Antitubercular
(sigh-kloe-SER-een)
Seromycin Pulvules
Class: Anti-infective/Antitubercular
Drugs Class ::
Action Inhibits cell wall synthesis in susceptible strains of certain microorganisms.
Indications for Drugs ::
Indications Treatment of active pulmonary and extrapulmonary tuberculosis when organisms are susceptible (after failure of adequate treatment with primary medications); treatment of urinary tract infections caused by susceptible bacteria when conventional therapy has failed; treatment of Gaucher’s disease.
Drug Dose ::
Route/Dosage
ADULTS: PO 250–500 mg q 12 hr; start with 250 mg q 12 hr for first 2 wk (maximum 1 g/day). CHILDREN: PO 10–20 mg/kg/day administered in 2 equally divided doses (maximum 1 g/day).
Contraindication ::
Contraindications Epilepsy; depression; severe anxiety or psychosis; severe renal insufficiency; excessive concurrent use of alcohol.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and dosage not well established. CNS toxicity: Discontinue drug or decrease dosage if symptoms of CNS toxicity develop. May be increased with excessive alcohol consumption. Pyridoxine 200–300 mg/day may be given to prevent neurotoxic effects. Renal impairment: Weekly blood levels of drug should be determined and dosage adjusted to keep blood levels < 30 mcg/ml.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: CHF. CNS: Convulsions; drowsiness; somnolence; headache; tremor; dysarthria; vertigo; confusion; loss of memory; psychoses with suicidal tendencies, behavior changes, hyperirritability, aggression, paresis; hyperreflexia; paresthesias; major and minor clonic seizures; coma; dizziness. DERM: Skin rash. HEPA: Elevated hepatic transaminase.
Drug Mode of Action ::
Action Inhibits cell wall synthesis in susceptible strains of certain microorganisms.
Drug Interactions ::
Interactions
Alcohol: Increases possibility and risk of epileptic episodes. Do not use together. Isoniazid: May increase cycloserine CNS side effects (eg, dizziness).
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Review history for epilepsy, depression, severe anxiety or psychosis, renal insufficiency or excessive alcohol use.
- Review liver function, BUN, creatinine and CBC before beginning therapy.
- Obtain culture before treatment and verify susceptibility when results are available.
- Perform baseline assessment of signs and symptoms of infection.
- If patient has active and infectious tuberculosis, institute infection control measures.
- Monitor serum cycloserine levels at least weekly in patients receiving > 500 mg/day and in patients with reduced renal function or symptoms of toxicity. Blood levels should remain < 30 mcg/ml.
- Monitor CBC, liver and renal function studies.
- If allergic dermatitis or symptoms of CNS toxicity, convulsions, psychosis, depression, headache, tremor, vertigo, paresis or dysarthria develop, withhold medication and notify physician.
- If CNS alterations occur, institute safety precautions.
- In patients with tuberculosis, assess for therapeutic effectiveness by monitoring clinical signs and symptoms, sputum cultures or smears for acid-fast bacilli and chest x-rays.
- In patients with urinary tract infections, assess for therapeutic effectiveness by monitoring clinical signs and symptoms and urine cultures.
|
Drug Storage/Management ::
Administration/Storage
- Administer with meals if GI irritation occurs.
- Store in airtight, light-resistant container at room temperature.
Drug Notes ::
Patient/Family Education
- Instruct patient that if depression or suicidal thoughts occur, notify physician immediately.
- Stress importance of regular follow-up visits to physician for ongoing assessment.
- If patient does not have adequate family support system, refer patient to community health organization for monitoring and support.
- Instruct patient to report these symptoms to physician: rash, anxiety, restlessness, confusion or tremor.
- Caution patient to avoid intake of alcoholic beverages because of increased risk of seizures.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.